Year: 2017-18

Company: Gilead Sciences

Liaison(s): Mike Green

Gilead Sciences is one of the top 5 pharmaceutical companies in U.S. with 30 years of track record in developing treatments for HIV, liver diseases, cancer malignancies and inflammatory conditions. It has several drugs for the above said conditions in the pipeline in various stages of development and approval processes. In 2017, Gilead acquired Kite Pharma and its therapy Yescarta became the first CAR-T therapy to be approved by the FDA for treatment of relapsing 2 B-Cell lymphoma.

The Team Master’s Project for Gilead pre-production focused on developing a pre-production tracking tool to help Gilead increase their efficiency. This involved creating documents for development and data recording. The completion of the documents was instrumental in designing the tool to capture specific pre-production process data. The data will be used to bring greater visibility to the life-cycle of required pre-production documents and highlight any potential delays so that the appropriate corrective measures can be taken. The team then focused on user acceptance testing (UAT) and hyper-care. UAT and hyper-care efforts focused on bringing to speed the pre-production user audience with using the tool. The training and hyper-care required the team to have full understanding of user experience and program functionality.